Literature DB >> 6274537

Chemosensitivity of human neoplasms with in vitro clone formation. Experience at the University of Southern California - Los Angeles County Medical Center.

J R Daniels, A M Daniels, E E Luck, B Whitman, J T Casagrande, D G Skinner.   

Abstract

We analyze experience with 600 specimens for in vitro chemosensitivity assessment of human neoplasms utilizing a soft agar colony-forming technique. Good test reproducibility is demonstrated. Disaggregation with collagenase enhances yield and does not alter chemosensitivity profiles. Therapeutic exposure to chemotherapy prior to biopsy reduces in vitro sensitivity to the specific agents used in vitro. The cyclophosphamide derivatives 4-hydroperoxycyclo phosphamide (4-HC) and phosphoramide mustard are active in vitro, and produce comparable rank order sensitivities among tested tumors. There is marked reduction of in vitro 4-HC sensitivity in patients with prior therapeutic cyclophosphamide exposure, supporting the use of this derivative in test systems. Rank order of test results among specimens is compared at 0.1 microgram and 10 microgram drug/ml. Substantial differences in rank order at these two dose levels are demonstrated, indicating that the in vitro test dose selected is an important variable.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274537     DOI: 10.1007/bf00256977

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

2.  4-hydroperoxidatin in the Fenton oxidation of the antitumor agent cyclophosphamide.

Authors:  J Van der Steen; E C Timmer; J G Westra; C Benckhuysen
Journal:  J Am Chem Soc       Date:  1973-10-31       Impact factor: 15.419

3.  A biologically active metabolite of cyclophosphamide.

Authors:  M Colvin; C A Padgett; C Fenselau
Journal:  Cancer Res       Date:  1973-04       Impact factor: 12.701

4.  Detection of induced tumour-resistance to cyclophosphamide by the in vitro short term test.

Authors:  M Volm; J Mattern; K Wayss
Journal:  Arch Gynakol       Date:  1977-11-29

5.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

6.  Primary bioassay of human tumor stem cells.

Authors:  A W Hamburger; S E Salmon
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

7.  Clonal growth of mammalian cells in vitro; growth characteristics of colonies from single HeLa cells with and without a feeder layer.

Authors:  T T PUCK; P I MARCUS; S J CIECIURA
Journal:  J Exp Med       Date:  1956-02-01       Impact factor: 14.307

  7 in total
  5 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Human tumor clonogenic assays. An overview.

Authors:  B I Sikic; R L Taber
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 4.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Human tumour clonogenicity in agar is improved by cell-free ascites.

Authors:  M P Uitendaal; H A Hubers; J G McVie; H M Pinedo
Journal:  Br J Cancer       Date:  1983-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.